Blair William & Co. IL Purchases 248,598 Shares of BWX Technologies, Inc. $BWXT

Blair William & Co. IL grew its position in BWX Technologies, Inc. (NYSE:BWXT) by 20.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,439,666 shares of the technology company’s stock after acquiring an additional 248,598 shares during the quarter. Blair William & Co. IL’s holdings in BWX Technologies were worth $248,832,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Aventura Private Wealth LLC purchased a new position in shares of BWX Technologies during the 4th quarter worth about $29,000. Strategic Advocates LLC bought a new position in BWX Technologies during the 3rd quarter valued at about $32,000. Strategic Investment Solutions Inc. IL raised its position in BWX Technologies by 300.0% in the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 200 shares of the technology company’s stock worth $37,000 after purchasing an additional 150 shares during the period. WFA of San Diego LLC purchased a new stake in BWX Technologies in the 2nd quarter worth about $29,000. Finally, Tucker Asset Management LLC bought a new stake in BWX Technologies in the fourth quarter worth about $36,000. Institutional investors own 94.39% of the company’s stock.

BWX Technologies Price Performance

BWX Technologies stock opened at $197.14 on Wednesday. The company has a debt-to-equity ratio of 1.58, a current ratio of 2.40 and a quick ratio of 2.33. The stock has a market cap of $18.06 billion, a price-to-earnings ratio of 52.71, a price-to-earnings-growth ratio of 3.19 and a beta of 0.73. The firm has a 50-day moving average of $208.73 and a two-hundred day moving average of $200.48. BWX Technologies, Inc. has a 1 year low of $133.84 and a 1 year high of $241.82.

BWX Technologies (NYSE:BWXT) last issued its earnings results on Monday, May 4th. The technology company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. BWX Technologies had a net margin of 10.20% and a return on equity of 31.33%. The business had revenue of $860.22 million for the quarter, compared to analyst estimates of $837.47 million. During the same period last year, the company posted $0.91 earnings per share. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. On average, research analysts forecast that BWX Technologies, Inc. will post 4.71 earnings per share for the current year.

BWX Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 5th. Shareholders of record on Tuesday, May 19th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, May 19th. BWX Technologies’s dividend payout ratio (DPR) is presently 28.88%.

Insiders Place Their Bets

In other news, CEO Rex D. Geveden sold 10,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $204.81, for a total transaction of $2,048,100.00. Following the transaction, the chief executive officer owned 202,491 shares of the company’s stock, valued at approximately $41,472,181.71. This represents a 4.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Thomas Fitzgerald sold 2,417 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $209.25, for a total value of $505,757.25. Following the transaction, the chief financial officer owned 6,884 shares in the company, valued at approximately $1,440,477. This represents a 25.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BWXT shares. Zacks Research lowered BWX Technologies from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. TD Securities initiated coverage on BWX Technologies in a report on Thursday, March 12th. They issued a “buy” rating and a $230.00 price target on the stock. Truist Financial boosted their price objective on BWX Technologies from $205.00 to $212.00 and gave the company a “hold” rating in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised BWX Technologies from a “hold” rating to a “buy” rating and upped their price objective for the company from $205.00 to $255.00 in a research report on Friday, May 15th. Finally, Wells Fargo & Company assumed coverage on BWX Technologies in a research note on Wednesday, April 1st. They issued an “underweight” rating and a $200.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.00.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.